{"name":"Australasian Leukaemia and Lymphoma Group","slug":"australasian-leukaemia-and-lymphoma-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5Ud2tlUUpGUE1TZXdON2pwQXAxVldibG9tcjFaS0ZqdmxHQXR3cDRFTU5RMTFYeFVaUU1rcEsyT2Nqc1FPdUZvWHI0TE9lcjR6UVFjcHRDMHNLWTVwbEFEVy13YVU?oc=5","date":"2026-01-23","type":"regulatory","source":"Wiley Online Library","summary":"Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study - Greenwood - 2026 - HemaSphere - Wiley Online Library","headline":"Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study - Greenwo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQTmJLUkI4VzZOTXN3aTlIODhUZjlGMURjSW45YzVUbmhjNy1CbEFpOXY4Nk16dkdaLUR6cnU1YjJiSkE2eGRiblFVNlZyNkJ5Z1gxY1JVczdyaDNfZ3lzYVJpdW91TXo0VEpqSlZJb3JxemZzUGFXdkJvNFo1cjJZYTJHelo1UVRWYV9FMzY0aHpvenVRbDBzYjBJRHVKdHpwb3hHdGxKSlJIRGZOQU1UUXBGN05mZkE2R0E?oc=5","date":"2025-11-17","type":"pipeline","source":"Forbes Australia","summary":"The Australian biotechs racing toward the next billion-dollar cancer drug - Forbes Australia","headline":"The Australian biotechs racing toward the next billion-dollar cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPTk42Y1pXd3laaEF5Z2N2X3Zlc2hjcGpaRFphNzVmcmthWUFDSE1pcWdBVUFtM1UyWTlBSkFaUXptX1R1d3hWVnV3aFJ1el9DclJUU3lhMFFqTjQ3RGRucWkya0V4bURyV01iRmtiNTRoNEVuYUhuOW1ZTjQtczRjeGxEdDBUNUFhNXJoSV9VMWpTakgy?oc=5","date":"2025-11-11","type":"trial","source":"Leukaemia Foundation","summary":"New trial aimed at keeping people with AML in remission - Leukaemia Foundation","headline":"New trial aimed at keeping people with AML in remission","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNVMwS3JuTkJ4M0N1ZlJIemNLTGhhQkg3bjRweU5xU2xaUUlWUU5uakhXSzZtU0xaaEVFaEJiY2Y4dkpSSXgyRkxLZFZUWDdNTnFwMTctbUktbWN6eGZOQmFFNk1VVVVsN0VnbkxWMGl4aGpxb2p1Qm1LZUhLZmhicTRzN3lZQ2xxczUxdzlINGJXOFhXdURNeUJ2YWxNTXhRUFoxcXhqcnh1UQ?oc=5","date":"2025-11-10","type":"trial","source":"Leukaemia Foundation","summary":"Spotlight on Professor Andrew Wei and the importance of clinical trials - Leukaemia Foundation","headline":"Spotlight on Professor Andrew Wei and the importance of clinical trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTmhEX3dDaVdlVHJ4VzFMVzV5LWVWRlVIRGZsMG0wNU01NTc3V2IwZUNFemRKWUVMNDgzZEZZdFluX2pxRU9aTGpPTkVUOUR3M2xLTzYtaHRnSklGMXZmc19tbXZxc3E5WWNiN2lsRTBxSEVsMHR5RGhxcmZZOHliS2UxMWlCUS1UNlZOZlBuclg0eG5yY2NtSG9WUXg1ZDFkdWhDcDd1Y18?oc=5","date":"2025-09-17","type":"pipeline","source":"RNZ","summary":"NZ's slow uptake of cancer treatments driving doctors offshore - RNZ","headline":"NZ's slow uptake of cancer treatments driving doctors offshore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBneWhDSlpoYmFqUlNOQUoteE01dHJ2Y1otSHhITmhtUExzdElJQm9RYWtXaDFqMm5PM3ByWVZtQktXYi1rZEUzdHdSQUIwT0EtVzJacUs5NXNWem5ITF8wdC0xa3VfeVB0c2lvcUNYSUNTODRjZmIxTFdNVFB6VVk?oc=5","date":"2025-09-08","type":"pipeline","source":"Fred Hutchinson Cancer Center","summary":"Novel drug regimen reduces risks of graft-versus-host disease - Fred Hutchinson Cancer Center","headline":"Novel drug regimen reduces risks of graft-versus-host disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxNTUpxcms5WG4xTkp4TkczVVo4eGVJaXRqWnFpby1VbUtJbFJhZ0lCa3NneTdpb2JPRUwzMTljbi1KZG5sdkg4cW9sQjQ4Wmh2bUNBOHYzN0NXSUw5RzBEMHZCV0JqczFXakVaLXRrajlHbnlJYldTeEZsSnpuR3VfcVB1eVBpSjhzMjhRTnVTVF84RTBOYmljRngzTl92LU5IQnN0QXJuU29WWFlRWHJUQ0lVQXVFWHAxeGFxSklRN1doVDVvMmM4ak5jZ1ZFclgycXFBYlltV2Uxam12R213M1dYbHJIbi05d3Nra1ZxeXZweXBGenV6Umk2QXMtY3FWSmozbG1GV2gzVW1yRTF4UENyQ2hxeldYeUhSVEtDMmVKVXM0aWJCUGJFajN3MHZTMU9fQjNodjVCSkQxMmNtSUN5S3c1dGNCTFYxLQ?oc=5","date":"2025-07-24","type":"pipeline","source":"European Medical Journal","summary":"Durable Responses to Lenzilumab: Azacitidine Combination Therapy in High Risk Proliferative Chronic Myelomonocytic Leukaemia with Suppression of CBL and RAS Mutant Subclones - European Medical Journal","headline":"Durable Responses to Lenzilumab: Azacitidine Combination Therapy in High Risk Proliferative Chronic Myelomonocytic Leuka","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQQ3p1dlVZa2dMLUd4SzBrYXdiVy1HTlFRMW9xaDlnbF9wVVZOWGNUbVZiWV9QOEY1eTdJbTZjTkVUaS1XR2UzbXhNZHkzOEtYOHRqMjJWUUN0Tl9TTlNZTlpkR3ZSNzE4QU9qMlc1YkV0QVVGY1hVX1ZoZHFPdUxHaTNFamFvZkQ3YVUyeVJHcUtHWi1xT2Jvc0RtM1NvWE9fT0pwcmZmcVhrTkFFQkZCNFJhY2ZEM2xzSkRqVDhiYVYzOFIzVlFDRmF0b1I?oc=5","date":"2025-06-17","type":"trial","source":"Oncology News Central","summary":"New Phase 3 Data Back Regimen as “the Major GVHD Prophylaxis,” Expert Says - Oncology News Central","headline":"New Phase 3 Data Back Regimen as “the Major GVHD Prophylaxis,” Expert Says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQWmZHWUN6QkppNncyOTJQc1cyTzI5RFMxRVNRSGtoSUxRYWFQNFlrRWFYaXdIYkE3ajBHWDh0MzYzTW12ZkgxbUM4Wk9KTm5sNUoweGdVVkNuczhic25EWTZYOG5VdlFoa3h5U2tPcWZySmtOMC1jTUl3MncwMXFRRGthbFhnczRhel9nMThyOHVjNjR6b04zSUxjSUVJdGY0?oc=5","date":"2024-09-05","type":"pipeline","source":"BioWorld News","summary":"Pharos Ibio wins MFDS orphan drug designation for AML drug - BioWorld News","headline":"Pharos Ibio wins MFDS orphan drug designation for AML drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQXJCOV8ybXhCQm1ORmw4X3h2ZDg5d3lua2FJVjlCZExDenNzZVJTU04wd2xkU2Rac3IxMWEyaHNYTmpqX2NQREd1VURIdVF6LUhzOEYwWloxV1VwOGxOQUxadF90VlNPVFA2Q2pPM3FBWF9ETUM4aDF6SEYzR2t4djVjZHY3OXdtQ05z?oc=5","date":"2024-07-03","type":"regulatory","source":"The Lancet","summary":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial - The","headline":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1oOXR5Q0hEeTNrY0hPbmZUdnMtZlB4UkxBdWNBYkJxbGVYMU84cmR4aGtRMkZ5aUQwTW9YTWYwSHkxdWxNcm5IS2FVd3FpWEpPMXZkcGZMNTNOTGI3b3ZN?oc=5","date":"2024-03-26","type":"trial","source":"Nature","summary":"How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials? - Nature","headline":"How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPRlRxMG1tSldMUmlveXh6NUxrbVJRcHBKa0tNYS1HVWMtb3A2ZHB0ME83MElUdmNha3gzUEhBWnk3Rk9NcjdfMW0wUy1BbWRZTzhMazFFdHJqTFJVamh5aFZZaVJZY181QWUxS2FJZmFsWXZQUmlwWXJudi10N3FzYTlkckZWX1RISXA0bUYxSEJDQU51N0VtcXJibExPQlBnaTBvcmZtMA?oc=5","date":"2021-05-14","type":"pipeline","source":"BioPharma APAC","summary":"Phebra's Confirm Bioequivalence of Oral and IV Formulations - BioPharma APAC","headline":"Phebra's Confirm Bioequivalence of Oral and IV Formulations","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}